The canine flea allergy dermatitis market is projected to grow from USD 3.1 billion in 2026 to USD 5.6 billion by 2036, at a CAGR of 6.1%. Isoxazoline products will dominate with a 42.0% market share, while chronic condition control will lead the acute flare management segment with a 44.0% share.